➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Express Scripts
Harvard Business School
McKesson
Moodys

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,962,590

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,962,590
Title:Prostate cancer vaccine
Abstract: Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.
Inventor(s): McNeel; Douglas G. (Madison, WI), Olson; Brian M. (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:13/968,854
Patent Claims:1. A method for inducing an immune reaction to androgen receptor in a mammal having prostate cancer, the method comprising the step of: administering to the mammal an effective amount of a DNA vaccine comprising a polynucleotide operatively linked to a transcriptional regulatory element, wherein the polynucleotide encodes a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain of the receptor, the ligand-binding domain fragment selected from the group consisting of (i) SEQ ID NO:9, (ii) SEQ ID NO:10, (iii) SEQ ID NO:11, and (iv) SEQ ID NO:12, whereby the mammal develops an immune reaction against androgen receptor.

2. The method of claim 1, wherein said DNA vaccine is administered in a pharmaceutically acceptable carrier.

3. The method of claim 1, wherein the DNA vaccine is a plasmid vector that comprises: (a) a backbone of pNGVL3; (b) the polynucleotide operably positioned in the backbone; and optionally (c) an immunostimulatory sequence (ISS) motif.

4. The method of claim 3, wherein: (a) the polynucleotide is operatively linked to a CMV promoter and to a CMV intron A for enhancing expression of the polynucleotide; and optionally (b) the optional immunostimulatory sequence (ISS) motif comprises at least one copy of 5'-GTCGTT-3'.

5. The method of claim 1, wherein the fragment is a fragment of a human androgen receptor.

6. The method of claim 1, wherein the vaccine is administered with a suitable amount of GM-CSF.

7. A method for inducing an immune reaction to androgen receptor in a mammal having prostate cancer, the method comprising the step of: administering to the mammal an effective amount of a plasmid vector comprising a polynucleotide operatively linked to a transcriptional regulatory element wherein the polynucleotide encodes a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain of the receptor, the ligand-binding domain fragment selected from the group consisting of (i) SEQ ID NO:9, (ii) SEQ ID NO:10, (iii) SEQ ID NO:11, and (iv) SEQ ID NO:12, whereby the mammal develops immune reaction against androgen receptor.

8. The method of claim 7, wherein the plasmid vector comprises: (a) a backbone of pNGVL3; (b) the polynucleotide operably positioned in the backbone; and optionally (c) an immunostimulatory sequence (ISS) motif.

9. The method of claim 7, wherein the plasmid vector comprises (a) the polynucleotide operatively linked to a CMV promoter and to a CMV intron A for enhancing expression of the polynucleotide; and optionally (b) the optional immunostimulatory sequence (ISS) motif comprises at least one copy of 5'-GTCGTT-3'.

10. The method of claim 7, wherein the fragment of a mammalian androgen receptor is a fragment of a human androgen receptor.

11. The method of claim 7, wherein the plasmid vector is administered in a pharmaceutically acceptable carrier.

12. The method of claim 7, wherein the plasmid vector is administered with a suitable amount of GM-CSF.

Details for Patent 8,962,590

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Wisconsin Alumni Research Foundation (Madison, WI) 2027-08-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Wisconsin Alumni Research Foundation (Madison, WI) 2027-08-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Wisconsin Alumni Research Foundation (Madison, WI) 2027-08-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Medtronic
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.